Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31465655 | 1.00 | NPSR1 (0.34) | NPSR1AAK1SSTR4ALDH1A1 | |
| SCHEMBL31304932 | 0.87 | ALDH1A1 (0.35) | NPSR1AAK1SSTR4ALDH1A1 | |
| SCHEMBL25426032 | 0.86 | — | — | |
| SCHEMBL25426028 | 0.86 | — | — | |
| SCHEMBL30449841 | 0.80 | MEN1 (0.34) | NPSR1AAK1 | |
| SCHEMBL31465653 | 0.80 | SSTR4 (0.34) | AAK1SSTR4 | |
| SCHEMBL25826819 | 0.79 | PPARA (0.37) | AAK1ALDH1A1 | |
| SCHEMBL31304931 | 0.78 | AAK1 (0.32) | AAK1 | |
| SCHEMBL31304904 | 0.78 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL29385268 | 0.76 | HTR2C (0.39) | NPSR1AAK1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739694-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025010294-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4460498-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | MAP3K20, MAP3K8, PRKACA | NPSR1 4776/4885AAK1 392/4885SSTR4 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.